Abstract Search

ea0070aep628 | Pituitary and Neuroendocrinology | ECE2020

Safety and IGF-1 levels with once daily oral sst2 agonist paltusotine (CRN00808) in acromegaly patients previously treated with peptide long-acting somatostatin receptor ligands: Initial data from the open label ACROBAT Edge phase 2 study

Toth Miklos , Gordon Murray , Doknic Mirjana , Mezosi Emese , Randeva Harpal , Marmon Tonya , Fowler Kim , Luo Rosa , Monahan Michael , Madan Ajay , Ferrara-Cook Chris , Scott Struthers R. , Krasner Alan

Peptide long-acting somatostatin receptor ligands (SRLs) are a first line medical treatment for acromegaly but are not efficiently absorbed when delivered orally. Years of injections with SRLs are associated with variable dose delivery, injection site reactions, and excessive life burden. Paltusotine (CRN00808) is a nonpeptide small molecule somatostatin type 2 (sst2) receptor agonist with high oral bioavailability (70%) and a 42–50 hour terminal elimination half-life in...

0 shares

ea0073oc15.4 | Oral Communications 15: Late Breaking | ECE2021

Identification of a dose range for once daily oral paltusotine in patients with acromegaly that maintains IGF-1 levels when switching from long-acting somatostatin receptor ligand therapy

Gordon Murray B. , Gadelha Monica , Toth Miklos , Doknic Mirjana , Mezosi Emese , Randeva Harpal , Marmon Tonya , Luo Rosa , Monahan Michael , Madan Ajay , Struthers Scott , Krasner Alan

Long-acting somatostatin receptor ligands (LA-SRLs) are a first line medical treatment for acromegaly but require monthly parenteral administration. Paltusotine (CRN00808) is a nonpeptide, small molecule somatostatin type 2 (SST2) receptor agonist with high oral bioavailability (70%), suitable for once daily, oral dosing. The recently reported results of the ACROBAT Edge study (NCT03789656) suggest that patients with acromegaly treated with injected SRLs can switch to once dai...

0 shares

Endocrine Abstracts

Safety and IGF-1 levels with once daily oral sst2 agonist paltusotine (CRN00808) in acromegaly patients previously treated with peptide long-acting somatostatin receptor ligands: Initial data from the open label ACROBAT Edge phase 2 study

Identification of a dose range for once daily oral paltusotine in patients with acromegaly that maintains IGF-1 levels when switching from long-acting somatostatin receptor ligand therapy

BiosciAbstracts